WO1989012689A1 - Method of obtaining a mixture of ribonucleotides - Google Patents
Method of obtaining a mixture of ribonucleotides Download PDFInfo
- Publication number
- WO1989012689A1 WO1989012689A1 PCT/SU1988/000269 SU8800269W WO8912689A1 WO 1989012689 A1 WO1989012689 A1 WO 1989012689A1 SU 8800269 W SU8800269 W SU 8800269W WO 8912689 A1 WO8912689 A1 WO 8912689A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- separation
- fraction
- temperature
- target product
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 22
- 108091028664 Ribonucleotide Proteins 0.000 title abstract description 5
- 239000002336 ribonucleotide Substances 0.000 title abstract description 5
- 125000002652 ribonucleotide group Chemical group 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000012528 membrane Substances 0.000 claims abstract description 17
- 238000000926 separation method Methods 0.000 claims description 9
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 abstract 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 239000000047 product Substances 0.000 description 27
- 235000019441 ethanol Nutrition 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229940081735 acetylcellulose Drugs 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Definitions
- the methods of obtaining a mixture of drugs known to provide healing properties (“Bulletin of Exterior Biology and Medicine”, 1969, Access /, J 9, p. 23-26) are known.
- the indicated 15 method is included in the case that the protein acid with a concentration of 5-10 mg / ml is processed at a temperature of 45 ° during the first hour.
- the indicated method is char- acterized by a low quality product.
- P ⁇ luchae maya mixture ⁇ ib ⁇ nu ⁇ le ⁇ id ⁇ v s ⁇ de ⁇ - 20 zhi ⁇ ⁇ imesi bel ⁇ a, vys ⁇ m ⁇ le ⁇ ulya ⁇ ny ⁇ ⁇ i ⁇ genyay ⁇ vesches ⁇ v, ⁇ e ⁇ mu v ⁇ zm ⁇ zhn ⁇ ⁇ l ⁇ its mes ⁇ n ⁇ e ⁇ imenenie as' na ⁇ uzh- ny ⁇ ⁇ vyaz ⁇ .
- the hydration of the fermented acid in the diet is 4.5-5.5, and the patient is hydrated;
- hydrolysis of the enzyme is a pan-regenerative ideal, while at a temperature of more than 65 ° C, partially evaporates
- Separation of the fraction of vibrations on membranes is preferable to a temperature of 20-30 ° ⁇ and pressure
- ⁇ sazhdenie mixture ⁇ ib ⁇ nu ⁇ le ⁇ id ⁇ v ⁇ bem ⁇ m e ⁇ an ⁇ la least 8 ⁇ a ⁇ n ⁇ g ⁇ not dae ⁇ v ⁇ zm ⁇ zhn ⁇ s ⁇ i ⁇ ln ⁇ s ⁇ yu ⁇ sv ⁇ b ⁇ di ⁇ sya ⁇ niz ⁇ m ⁇ le ⁇ ulya ⁇ ny ⁇ ⁇ i ⁇ genny ⁇ s ⁇ e of the connections 10, 10 ⁇ sazhdenie b ⁇ lee ⁇ a ⁇ nym ⁇ bem ⁇ m e ⁇ an ⁇ la not ⁇ iv ⁇ di ⁇ ⁇ increase ⁇ l ⁇ zhi ⁇ eln ⁇ g ⁇ e ⁇ e ⁇ a.
- the inventive method allows to increase the output of the target product by 8-15 by comparison with the known method, and also to increase the cost-benefit of the product. 25 BEST MODE FOR CARRYING OUT THE INVENTION
- the claimed method is as follows. Fermented acid is suspended in distilled water, and alkaline products are 4.5–5.5 alkaline. Then, in the case of the distributor, the add-on acid add the enzyme 30 to the fungicidal agent, heat the agent up to 62-65 ° ⁇ and the extractor is hydrated After the end of the hydrolysis, it is refrigerated, added to it ethanol and mixed. In order to separate the small precipitate that has grown after adding 35 ethanol, the mixture is micromotor-assisted. Then, the illuminated device is activated by ultrafiltration through a membrane with a size of 50-150 ⁇ , preferably at a temperature of 20-30 ° C and a pressure of 0.1-30 ° C. After office,
- the filter for concentrate will add the distilled water and will receive an additional quantity of filter.
- the amount of ultrafilter adds to the mixing of ethanol. After the mixture has been left to stand, the horticultural liquid is removed from the product and the sediment is washed off. The target product may be received as dry, as well as in the form of a solution. For this mixture of ribo-nucleotides, isolated after the deposition of 8-10 large-scale plants
- the resulting target product is white
- the total capacity of the hydrolysis is 465 ml. Then it is cooled to a temperature of 25-35 ° C, it is added 120 ml of ethanol, the filter is removed and the particulate is filtered and it is particulate.
- the resulting yellow color filter is filtered through a black and white filter, and then through a membrane with a pressure of 2000 psi and a pressure of 98 kPa.
- Example 2 Separated sludge (39 g of dry mix) is dissolved in a 0.55% solution of hydrochloride (995 ml) when the water is removed and the water is removed. The resulting yellow color filter is filtered through a black and white filter, and then through a membrane with a high pressure of 2200 ⁇ - 8 - ⁇ and a pressure of 78 ⁇ Pa. Dispensing the unit under stable conditions dilutes the ampoules from the neutral glass at 3 ml and waits for processing in the autoclave at a temperature of 32. Concentration of vibrators in order to
- a mixture of drugs obtained by the claimed method is used in medical practice as a medicine for the treatment of therapeutic abnormalities.
- the indicated mixture may be used for the treatment of myopathy, a number of immunodeficiencies, injuries, burns and other illnesses—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19883891346 DE3891346T1 (de) | 1988-12-20 | 1988-12-20 | Verfahren zur herstellung des ribonukleotidengemisches |
| GB9002774A GB2231052A (en) | 1988-06-14 | 1990-02-08 | Method of preparing a mixture of ribonucleotides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU4432648/28 | 1988-06-14 | ||
| SU884432648A SU1575359A1 (ru) | 1988-06-14 | 1988-06-14 | Способ получени рибонуклеотидов |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1989012689A1 true WO1989012689A1 (en) | 1989-12-28 |
Family
ID=21378060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SU1988/000269 WO1989012689A1 (en) | 1988-06-14 | 1988-12-20 | Method of obtaining a mixture of ribonucleotides |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5064758A (forum.php) |
| JP (1) | JPH03501563A (forum.php) |
| CN (1) | CN1053090A (forum.php) |
| ES (1) | ES2010913A6 (forum.php) |
| FR (1) | FR2635533A1 (forum.php) |
| GB (1) | GB2231052A (forum.php) |
| IN (1) | IN168260B (forum.php) |
| IT (1) | IT1229178B (forum.php) |
| PL (1) | PL278876A1 (forum.php) |
| SU (1) | SU1575359A1 (forum.php) |
| WO (1) | WO1989012689A1 (forum.php) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013089835A1 (en) | 2011-12-12 | 2013-06-20 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1110567C (zh) * | 2000-02-17 | 2003-06-04 | 北京太宫生物技术有限责任公司 | 脱氧核糖核苷三磷酸的制备方法 |
| RU2274658C2 (ru) * | 2004-02-03 | 2006-04-20 | Российский химико-технологический университет им. Д.И. Менделеева | Способ получения панкреатического гидролизата рибонуклеиновой кислоты |
| RU2244008C1 (ru) * | 2004-02-05 | 2005-01-10 | Закрытое акционерное общество "Биоамид" | Усовершенствованный способ получения нуклеината натрия |
| JP4810164B2 (ja) * | 2004-09-03 | 2011-11-09 | 富士フイルム株式会社 | 核酸分離精製方法 |
| RU2392329C1 (ru) * | 2008-10-07 | 2010-06-20 | Общество с ограниченной ответственностью "ВИТАЛАНГ" | Способ получения высокополимерной рнк из дрожжей |
| CN112544827B (zh) * | 2020-12-08 | 2024-01-30 | 南京工业大学 | 一种罗氏沼虾饲料添加剂及其制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920519A (en) * | 1973-02-14 | 1975-11-18 | Yuh Norimoto | Enzymatic hydrolysis of ribonucleic acid |
| US4190649A (en) * | 1976-06-03 | 1980-02-26 | Mirko Beljanski | Polyribonucleotides capable of promoting the genesis of leucocytes and blood platelets |
| DE1941709C3 (de) * | 1969-08-16 | 1981-07-16 | Diether Prof. Dr. Bern Jachertz | Verfahren zur enzymatischen Vermehrung von informatorischer Ribonucleinsäure |
| EP0149775A1 (en) * | 1983-12-09 | 1985-07-31 | Otsuka Pharmaceutical Factory, Inc. | Compositions of nucleic acid components |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1194709B (de) * | 1960-05-25 | 1965-06-10 | Voith Gmbh J M | Drehservomotor, insbesondere zum Verstellen der Leitschaufeln von Wasserturbinen |
-
1988
- 1988-06-14 SU SU884432648A patent/SU1575359A1/ru active
- 1988-12-20 US US07/460,921 patent/US5064758A/en not_active Expired - Fee Related
- 1988-12-20 JP JP1503843A patent/JPH03501563A/ja active Pending
- 1988-12-20 WO PCT/SU1988/000269 patent/WO1989012689A1/ru active Application Filing
-
1989
- 1989-03-30 IN IN245/CAL/89A patent/IN168260B/en unknown
- 1989-04-03 CN CN89102805A patent/CN1053090A/zh active Pending
- 1989-04-03 FR FR8904370A patent/FR2635533A1/fr not_active Withdrawn
- 1989-04-06 ES ES8901200A patent/ES2010913A6/es not_active Expired
- 1989-04-07 IT IT8920064A patent/IT1229178B/it active
- 1989-04-14 PL PL27887689A patent/PL278876A1/xx unknown
-
1990
- 1990-02-08 GB GB9002774A patent/GB2231052A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1941709C3 (de) * | 1969-08-16 | 1981-07-16 | Diether Prof. Dr. Bern Jachertz | Verfahren zur enzymatischen Vermehrung von informatorischer Ribonucleinsäure |
| US3920519A (en) * | 1973-02-14 | 1975-11-18 | Yuh Norimoto | Enzymatic hydrolysis of ribonucleic acid |
| US4190649A (en) * | 1976-06-03 | 1980-02-26 | Mirko Beljanski | Polyribonucleotides capable of promoting the genesis of leucocytes and blood platelets |
| EP0149775A1 (en) * | 1983-12-09 | 1985-07-31 | Otsuka Pharmaceutical Factory, Inc. | Compositions of nucleic acid components |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013089835A1 (en) | 2011-12-12 | 2013-06-20 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| EP2790722A4 (en) * | 2011-12-12 | 2015-09-09 | Univ Illinois | COMPOSITION AND METHOD FOR THE TREATMENT OF EYE DISEASES RELATED TO NUCLEIC ACID |
| US9867871B2 (en) | 2011-12-12 | 2018-01-16 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| US10328129B2 (en) | 2011-12-12 | 2019-06-25 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
| US11376312B2 (en) | 2011-12-12 | 2022-07-05 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating nucleic acid-related eye disease |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9002774D0 (en) | 1990-07-11 |
| PL278876A1 (en) | 1989-12-27 |
| IT8920064A0 (it) | 1989-04-07 |
| US5064758A (en) | 1991-11-12 |
| SU1575359A1 (ru) | 1991-05-15 |
| CN1053090A (zh) | 1991-07-17 |
| FR2635533A1 (fr) | 1990-02-23 |
| JPH03501563A (ja) | 1991-04-11 |
| IT1229178B (it) | 1991-07-23 |
| IN168260B (forum.php) | 1991-03-02 |
| GB2231052A (en) | 1990-11-07 |
| ES2010913A6 (es) | 1989-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002078694A1 (fr) | Photosensibilisateur et procede pour produire ledit photosensibilisateur | |
| CN115074357B (zh) | 一种多聚脱氧核糖核苷酸的制备方法及应用 | |
| CN106832036A (zh) | 海藻多糖提取物的制备方法 | |
| CN102070727A (zh) | 一种肝素钠的提取方法 | |
| WO1989012689A1 (en) | Method of obtaining a mixture of ribonucleotides | |
| CN1014323B (zh) | 由松子外壳中提取生理活性物质的方法 | |
| JPH02171185A (ja) | 生理活性物質の調製方法 | |
| RU2088112C1 (ru) | Способ получения свекловичного пектина | |
| CN112079938A (zh) | 一种青稞多糖的提取方法、青稞多糖提取物及其应用 | |
| RU2189990C1 (ru) | Способ получения высокоочищенного агара и агарозы из красной водоросли анфельции тобучинской | |
| RU2137486C1 (ru) | Аллогенный препарат плаценты человека, обладающий противовоспалительным, репаративным, антимикробным, ранозаживляющим действием, и способ его получения | |
| US4315923A (en) | Process for the production of organ extracts with high herparin content | |
| US4473556A (en) | Composition and method for treating gastrointestinal disturbances in animals and method for producing this composition | |
| RU2017751C1 (ru) | Способ получения гиалуроновой кислоты | |
| WO1994004551A1 (en) | Method of obtaining sodium salt of native dna | |
| KR20110056346A (ko) | 고순도의 의료용 히아루론산의 제조 방법 | |
| RU2769508C2 (ru) | Способ получения комбинированного препарата из плаценты животных и фитосырья | |
| CN109652486B (zh) | 一种小分子大青叶螯合肽的制备方法 | |
| RU2090207C1 (ru) | Способ получения гиалуронидазы | |
| RU2052265C1 (ru) | Способ получения препарата гиалуроновой кислоты для использования в офтальмологии | |
| US2987443A (en) | Process of producing biosplen | |
| KR840001510B1 (ko) | 삼지구엽초 sp속 식물로부터의 추출물 제조방법 | |
| RU2201101C2 (ru) | Способ обработки грубых кормов | |
| RU2274658C2 (ru) | Способ получения панкреатического гидролизата рибонуклеиновой кислоты | |
| RU2278678C2 (ru) | Способ получения препарата для повышения резистентности организма животных |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): DE GB HU JP US |
|
| RET | De translation (de og part 6b) |
Ref document number: 3891346 Country of ref document: DE Date of ref document: 19900607 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 3891346 Country of ref document: DE |